{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:49:04Z","timestamp":1792651744052,"version":"4.5.0"},"reference-count":408,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82225029"],"award-info":[{"award-number":["82225029"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302628"],"award-info":[{"award-number":["82302628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402704"],"award-info":[{"award-number":["82402704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301987"],"award-info":[{"award-number":["82301987"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301989"],"award-info":[{"award-number":["82301989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82430076"],"award-info":[{"award-number":["82430076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.apsb.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:04:10Z","timestamp":1750680250000},"page":"3852-3887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects"],"prefix":"10.1016","volume":"15","author":[{"given":"Xueni","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-3066","authenticated-orcid":false,"given":"Chenhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.06.013_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/21505594.2016.1158359","article-title":"Bloodstream infections in HIV-infected patients","volume":"7","author":"Taramasso","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.apsb.2025.06.013_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-319-04220-6_4","article-title":"Fungal infections in cancer patients","volume":"161","author":"Angarone","year":"2014","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000488539","article-title":"Antifungal innate immunity: a perspective from the last 10 years","volume":"10","author":"Salazar","year":"2018","journal-title":"J Innate Immun"},{"key":"10.1016\/j.apsb.2025.06.013_bib4","article-title":"The evolution of antifungal therapy: traditional agents, current challenges and future perspectives","volume":"8","author":"Souza","year":"2025","journal-title":"Curr Res Microb Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/14656566.2021.1892075","article-title":"An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections","volume":"22","author":"Mueller","year":"2021","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.apsb.2025.06.013_bib6","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.ejim.2016.09.005","article-title":"Critically ill patients at risk of invasive candidiasis: the \u201cdilemma\u201d of the best antifungal treatment strategy","volume":"37","author":"Antinori","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkx388","article-title":"A systematic review of interventions and performance measures for antifungal stewardship programmes","volume":"73","author":"Bienvenu","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib8","first-page":"341","article-title":"Antifungals in clinical use and the pipeline","volume":"35","author":"Johnson","year":"2021","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.apsb.2025.06.013_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11046-023-00759-5","article-title":"The role of novel antifungals in the management of candidiasis: a clinical perspective","volume":"188","author":"Ordaya","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.apsb.2025.06.013_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00142-23","article-title":"Advancements and challenges in antifungal therapeutic development","volume":"37","author":"Puumala","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00003-23","article-title":"Recent progress in research on mitochondrion-targeted antifungal drugs: a review","volume":"67","author":"Qin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib12","first-page":"1687","article-title":"Progress of research on azole resistance in Aspergillus fumigatus","volume":"37","author":"Chen","year":"2016","journal-title":"Chin J Epidemiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib13","article-title":"Fungal infections, treatment and antifungal resistance: the sub-saharan african context","volume":"11","author":"Boakye-Yiadom","year":"2024","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.fgb.2019.103254","article-title":"Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi","volume":"132","author":"Hokken","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2021.09.071","article-title":"Antifungal drug resistance: deciphering the mechanisms governing multidrug resistance in the fungal pathogen Candida glabrata","volume":"31","author":"Robbins","year":"2021","journal-title":"Curr Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2019.100915","article-title":"Exploring the molecular mechanism of azole resistance in Aspergillus fumigatus","volume":"30","author":"Chen","year":"2020","journal-title":"J Mycol Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.44.1.63-67.2000","article-title":"The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity","volume":"44","author":"Lamb","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib19","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1128\/AAC.00027-12","article-title":"The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata","volume":"56","author":"Shields","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/cit140","article-title":"Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida","volume":"56","author":"Ostrosky-Zeichner","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138945006776359403","article-title":"Fungal ATP-binding cassette (ABC) transporters in drug resistance & detoxification","volume":"7","author":"Sipos","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.apsb.2025.06.013_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11046-023-00727-z","article-title":"Treatment of invasive aspergillosis: how it\u2019s going, where it\u2019s heading","volume":"188","author":"Boyer","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.apsb.2025.06.013_bib23","article-title":"MFS transporters of Candida species and their role in clinical drug resistance","volume":"16","author":"A","year":"2016","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02594-23","article-title":"Characterization of a selective, iron-chelating antifungal compound that disrupts fungal metabolism and synergizes with fluconazole","volume":"12","author":"Corrales","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.06.013_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242317026","article-title":"Anti-biofilm activity of cocultimycin a against Candida albicans","volume":"24","author":"Zhu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MB-0008-2014","article-title":"Fungal biofilms: in vivo models for discovery of anti-biofilm drugs","volume":"3","author":"Nett","year":"2015","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.06.013_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcb.30163","article-title":"Target-based drug repurposing against Candida albicans\u2014a computational modeling, docking, and molecular dynamic simulations study","volume":"123","author":"Verma","year":"2022","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2025.06.013_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00633-24","article-title":"The small molecule CBR-5884 inhibits the Candida albicans phosphatidylserine synthase","volume":"15","author":"Zhou","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.06.013_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.apsb.2024.08.017","article-title":"GSFM: a genome-scale functional module transformation to represent drug efficacy for in silico drug discovery","volume":"15","author":"Tian","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib30","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.apsb.2024.03.002","article-title":"In silico off-target profiling for enhanced drug safety assessment","volume":"14","author":"Liu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.apsb.2023.11.027","article-title":"Automated and miniaturized screening of antibiotic combinations via robotic-printed combinatorial droplet platform","volume":"14","author":"Shao","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","article-title":"Antifungals","volume":"133","author":"Campoy","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2025.06.013_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.copbio.2021.02.001","article-title":"Antifungal natural products","volume":"69","author":"Heard","year":"2021","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.apsb.2025.06.013_bib34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/ph14050488","article-title":"Drug repurposing in medical mycology: identification of compounds as potential antifungals to overcome the emergence of multidrug-resistant fungi","volume":"14","author":"Peyclit","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2025.06.013_bib35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/antibiotics9110812","article-title":"Antifungal drug repurposing","volume":"9","author":"Kim","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib36","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.drudis.2022.04.021","article-title":"Repurposing and optimization of drugs for discovery of novel antifungals","volume":"27","author":"Donlin","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.06.013_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1568006033481438","article-title":"Novel immunotherapeutic strategies for invasive fungal disease","volume":"3","author":"van Spriel","year":"2003","journal-title":"Curr Drug Targets Cardiovasc Hematol Disord"},{"key":"10.1016\/j.apsb.2025.06.013_bib38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/08820139.2015.1093913","article-title":"Immunotherapy of fungal infections","volume":"44","author":"Datta","year":"2015","journal-title":"Immunol Investig"},{"key":"10.1016\/j.apsb.2025.06.013_bib39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.biopha.2018.12.009","article-title":"Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases","volume":"110","author":"Nami","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.06.013_bib40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/1566524023666230302123310","article-title":"Molecular targeting and novel therapeutic approaches against fungal infections","volume":"23","author":"Kumar","year":"2023","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib42","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1016\/j.apsb.2023.08.010","article-title":"Emerging drug design strategies in anti-influenza drug discovery","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1039\/D4NP00044G","article-title":"Fungerps: discovery of the glucan synthase inhibitor enfumafungin and development of a new class of antifungal triterpene glycosides","volume":"41","author":"Vicente","year":"2024","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.apsb.2025.06.013_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"Wiederhold","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5223(19)35754-X","article-title":"The impact of distal aortic perfusion and somatosensory evoked potential monitoring on prevention of paraplegia after aortic aneurysm operation","volume":"95","author":"Crawford","year":"1988","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.apsb.2025.06.013_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/jof6040261","article-title":"Nikkomycin Z-Ready to meet the promise?.","volume":"6","author":"Larwood","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/v15010197","article-title":"Polymycovirus infection sensitizes Aspergillus fumigatus for antifungal effects of nikkomycin Z","volume":"15","author":"Sass","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2025.06.013_bib48","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/AAC.44.6.1624-1629.2000","article-title":"Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model","volume":"44","author":"Goldberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/phar.2926","article-title":"Management of invasive candidiasis: a focus on rezafungin, ibrexafungerp, and fosmanogepix","volume":"44","author":"August","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.apsb.2025.06.013_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0043-1776776","article-title":"Antifungal therapies for Aspergillus spp.: present and future","volume":"45","author":"Eschenauer","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126713","article-title":"Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp.","volume":"29","author":"Trzoss","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.06.013_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01132-23","article-title":"In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)","volume":"68","author":"Pfaller","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib53","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/jof8111144","article-title":"Recent antifungal pipeline developments against Candida auris: a systematic review","volume":"8","author":"Trevi\u00f1o-Rangel","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cmi.2024.03.006","article-title":"New treatment options for critically important WHO fungal priority pathogens","volume":"31","author":"Kriegl","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.apsb.2025.06.013_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.152061","article-title":"Chiral fungicide penconazole: absolute configuration, bioactivity, toxicity, and stereoselective degradation in apples","volume":"808","author":"Li","year":"2022","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.apsb.2025.06.013_bib56","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/pathogens13100886","article-title":"Outcomes of invasive fungal infections treated with isavuconazole: a retrospective review","volume":"13","author":"Gow-Lee","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.apsb.2025.06.013_bib57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/jof7050376","article-title":"Penetration of isavuconazole in ascites fluid of critically ill patients","volume":"7","author":"Lahmer","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4067\/s0716-10182020000300219","article-title":"Azoles of then and now: a review","volume":"37","author":"Nocua-B\u00e1ez","year":"2020","journal-title":"Rev Chilena Infectol"},{"key":"10.1016\/j.apsb.2025.06.013_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae346","article-title":"Oral lipid nanocrystal amphotericin B (MAT2203) for the treatment of invasive fungal infections","volume":"11","author":"Dalton","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib60","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41586-023-06710-4","article-title":"Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal","volume":"623","author":"Maji","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.06.013_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myae032","article-title":"Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598","volume":"62","author":"Gu","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/10600280231195649","article-title":"Oteseconazole for the treatment of recurrent vulvovaginal candidiasis: a drug review","volume":"58","author":"Lanier","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.apsb.2025.06.013_bib63","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12879-024-10143-3","article-title":"Review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/jof7020130","article-title":"Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential","volume":"7","author":"Wiederhold","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02689-18","article-title":"ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib66","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.biopha.2017.11.127","article-title":"Recent advances in delivery of antifungal agents for therapeutic management of candidiasis","volume":"96","author":"Sawant","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.06.013_bib67","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.apsb.2025.06.013_bib68","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.06.013_bib69","first-page":"e172","article-title":"Therapeutic tools for oral candidiasis: current and new antifungal drugs","volume":"24","author":"Quind\u00f3s","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.apsb.2025.06.013_bib70","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.apsb.2025.06.013_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/019459988509300129","article-title":"Ketoconazole and the antifungals","volume":"93","author":"Parkin","year":"1985","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.apsb.2025.06.013_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2024.101473","article-title":"Itraconazole in human medicine and veterinary practice","volume":"34","author":"Sousa","year":"2024","journal-title":"J Mycol Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib73","first-page":"11","article-title":"Naftifine: a topical allylamine for superficial dermatophytosis","volume":"71","author":"Trailokya","year":"2023","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.apsb.2025.06.013_bib74","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.FUNK-0035-2016","article-title":"The fungal cell wall: structure, biosynthesis, and function","volume":"5","author":"Gow","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.06.013_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.02.008","article-title":"The fungal cell wall as a target for the development of new antifungal therapies","volume":"37","author":"Cort\u00e9s","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.apsb.2025.06.013_bib77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-023-05856-5","article-title":"Structural and mechanistic insights into fungal \u03b2-1,3-glucan synthase FKS1","volume":"616","author":"Hu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.06.013_bib78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biortech.2017.09.113","article-title":"The FKS family genes cause changes in cell wall morphology resulted in regulation of anti-autolytic ability in Saccharomyces cerevisiae","volume":"249","author":"Wang","year":"2018","journal-title":"Bioresour Technol"},{"key":"10.1016\/j.apsb.2025.06.013_bib79","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1128\/AAC.00432-11","article-title":"Discovery of a novel class of orally active antifungal beta-1,3-d-glucan synthase inhibitors","volume":"55","author":"Walker","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib81","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2024.02.007","article-title":"Targeting Fks1 proteins for novel antifungal drug discovery","volume":"45","author":"Kumar","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib82","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib83","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated Candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, scy-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib87","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib88","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DDDT.S339349","article-title":"Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy","volume":"17","author":"Phillips","year":"2023","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2025.06.013_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107359","article-title":"Vulvovaginal candidiasis\u2014an overview of current trends and the latest treatment strategies","volume":"200","author":"Bhosale","year":"2025","journal-title":"Microb Pathog"},{"key":"10.1016\/j.apsb.2025.06.013_bib90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/jof7030163","article-title":"Ibrexafungerp: a first-in-class oral triterpenoid glucan synthase inhibitor","volume":"7","author":"Jallow","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1471-0528.16972","article-title":"Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306)","volume":"129","author":"Sobel","year":"2022","journal-title":"Bjog"},{"key":"10.1016\/j.apsb.2025.06.013_bib92","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/jof6040262","article-title":"Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins","volume":"6","author":"Garcia-Effron","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.apsb.2025.06.013_bib94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: a novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/17425255.2024.2424899","article-title":"Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation","volume":"21","author":"Bassetti","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.apsb.2025.06.013_bib96","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/microorganisms9040863","article-title":"Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four Candida auris clades in RPMI-1640 in the absence and presence of human serum","volume":"9","author":"Kov\u00e1cs","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2025.06.013_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00099-20","article-title":"Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018)","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib99","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib100","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib101","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib103","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of Candidaemia and invasive Candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.06.013_bib105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fmicb.2013.00149","article-title":"Bacterial chitin degradation-mechanisms and ecophysiological strategies","volume":"4","author":"Beier","year":"2013","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib106","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1038\/s41467-023-40479-4","article-title":"Structure, catalysis, chitin transport, and selective inhibition of chitin synthase","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.06.013_bib107","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41594-022-00791-x","article-title":"Structural basis for inhibition and regulation of a chitin synthase from Candida albicans","volume":"29","author":"Ren","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/op3003294","article-title":"A practical and scalable manufacturing process for an anti-fungal agent, Nikkomycin Z","volume":"17","author":"Stenland","year":"2013","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.apsb.2025.06.013_bib109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1475-2859-8-61","article-title":"Selectively improving nikkomycin Z production by blocking the imidazolone biosynthetic pathway of nikkomycin X and uracil feeding in Streptomyces ansochromogenes","volume":"8","author":"Liao","year":"2009","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.apsb.2025.06.013_bib110","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.42.9.2371","article-title":"Efficacy of nikkomycin Z in the treatment of murine histoplasmosis","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib111","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/13693786.2013.770610","article-title":"Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs","volume":"51","author":"Shubitz","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib112","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/AAC.34.4.587","article-title":"Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis","volume":"34","author":"Hector","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib113","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1469-0691.2004.00996.x","article-title":"In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus","volume":"10","author":"Ganesan","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.apsb.2025.06.013_bib114","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00619-17","article-title":"Effects of echinocandins in combination with Nikkomycin Z against invasive Candida albicans bloodstream isolates and the fks mutants","volume":"61","author":"Cheung","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib115","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.43.6.1401","article-title":"In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole","volume":"43","author":"Li","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib116","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01609-08","article-title":"Pharmacokinetics of nikkomycin Z after single rising oral doses","volume":"53","author":"Nix","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib117","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12281-021-00419-5","article-title":"Investigational agents for the treatment of resistant yeasts and molds","volume":"15","author":"Seiler","year":"2021","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.apsb.2025.06.013_bib118","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4155\/fmc-2016-0110","article-title":"The GPI anchor pathway: a promising antifungal target?","volume":"8","author":"Mutz","year":"2016","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/id5000212","article-title":"Chemical genomics-based antifungal drug discovery: targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis","volume":"1","author":"Mann","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib120","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1091\/mbc.11.4.1183","article-title":"Leishmania mexicana mutants lacking glycosylphosphatidylinositol (GPI):protein transamidase provide insights into the biosynthesis and functions of GPI-anchored proteins","volume":"11","author":"Hilley","year":"2000","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.apsb.2025.06.013_bib121","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00899-20","article-title":"Antifungal activity of gepinacin scaffold glycosylphosphatidylinositol anchor biosynthesis inhibitors with improved metabolic stability","volume":"64","author":"Liston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib122","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib123","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1038\/s41467-024-53512-x","article-title":"Structural insights into the inhibition mechanism of fungal GWT1 by manogepix","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.06.013_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/znc-2016-0156","article-title":"Structural diversity in echinocandin biosynthesis: the impact of oxidation steps and approaches toward an evolutionary explanation","volume":"72","author":"H\u00fcttel","year":"2017","journal-title":"Z Naturforsch, C: J Biosci"},{"key":"10.1016\/j.apsb.2025.06.013_bib125","doi-asserted-by":"crossref","first-page":"23639","DOI":"10.1074\/jbc.M301044200","article-title":"GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast","volume":"278","author":"Umemura","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib127","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and Hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib128","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib129","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris. Antimicrob Agents Chemother","volume":"62","author":"Hager","year":"2018"},{"key":"10.1016\/j.apsb.2025.06.013_bib130","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00294-019-00987-7","article-title":"Identification and functional characterization of Candida albicans mannose-ethanolamine phosphotransferase (Mcd4p)","volume":"65","author":"Hasegawa","year":"2019","journal-title":"Curr Genet"},{"key":"10.1016\/j.apsb.2025.06.013_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.911322","article-title":"Novel promising antifungal target proteins for conquering invasive fungal infections","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib132","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1038\/s41467-020-17221-5","article-title":"Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14\/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.06.013_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153556","article-title":"Natural products targeting the synthesis of \u03b2(1,3)-d-glucan and chitin of the fungal cell wall. Existing drugs and recent findings","volume":"88","author":"Curto","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.apsb.2025.06.013_bib134","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fitote.2018.05.003","article-title":"Effect of nagilactone E on cell morphology and glucan biosynthesis in budding yeast Saccharomyces cerevisiae","volume":"128","author":"Hayashi","year":"2018","journal-title":"Fitoterapia"},{"key":"10.1016\/j.apsb.2025.06.013_bib135","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1745-7254.2008.00900.x","article-title":"Effect of plagiochin E, an antifungal macrocyclic bis(bibenzyl), on cell wall chitin synthesis in Candida albicans","volume":"29","author":"Wu","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.06.013_bib136","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tcsw.2018.09.001","article-title":"Yeast species-specific, differential inhibition of \u03b2-1,3-glucan synthesis by poacic acid and caspofungin","volume":"3","author":"Lee","year":"2018","journal-title":"Cell Surf"},{"key":"10.1016\/j.apsb.2025.06.013_bib137","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21307\/pjm-2018-054","article-title":"Emodin reduces the activity of (1,3)-\u03b2-d-glucan synthase from Candida albicans and does not interact with caspofungin","volume":"67","author":"Janeczko","year":"2018","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib138","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12906-021-03468-y","article-title":"Effect of Cinnamaldehyde on C. albicans cell wall and (1,3)-\u03b2-d-glucans in vivo","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Complement Med Ther"},{"key":"10.1016\/j.apsb.2025.06.013_bib139","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/jam.13301","article-title":"Fungal cell membrane-promising drug target for antifungal therapy","volume":"121","author":"Sant","year":"2016","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105878","article-title":"Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in Aspergillus fumigatus infected mice: pulmonary PK-PD analysis of anti-fungal PC945","volume":"163","author":"Ito","year":"2021","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib141","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-16","article-title":"In vitro and in vivo antifungal profile of a novel and long-acting inhaled azole, PC945, on Aspergillus fumigatus infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib142","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dkz280","article-title":"In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris","volume":"74","author":"Rudramurthy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib143","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1038\/s41598-019-45890-w","article-title":"Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection","volume":"9","author":"Colley","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.06.013_bib144","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib145","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/TCRM.S90335","article-title":"Role of isavuconazole in the treatment of invasive fungal infections","volume":"12","author":"Wilson","year":"2016","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.apsb.2025.06.013_bib146","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.2015.990382","article-title":"Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases","volume":"13","author":"Seyedmousavi","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.apsb.2025.06.013_bib147","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib148","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib149","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib151","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.apsb.2025.06.013_bib152","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.06.013_bib153","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1128\/AAC.00349-16","article-title":"The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus Species CYP51 but only weakly inhibits the human enzyme","volume":"60","author":"Warrilow","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib154","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.apsb.2025.06.013_bib156","article-title":"Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib157","article-title":"In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib158","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.02770-15","article-title":"The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii","volume":"60","author":"Lockhart","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib159","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02258-17","article-title":"The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib160","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/jac\/dky242","article-title":"The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis","volume":"73","author":"Garvey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib161","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/jac\/dky170","article-title":"VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice","volume":"73","author":"Break","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib162","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib163","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/microorganisms11020237","article-title":"VT-1161-A tetrazole for management of mono- and dual-species biofilms","volume":"11","author":"Maione","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2025.06.013_bib164","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14787210.2020.1792288","article-title":"Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies","volume":"18","author":"Mota Fernandes","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.apsb.2025.06.013_bib165","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/acs.jmedchem.9b01004","article-title":"SAR studies on aromatic acylhydrazone-based inhibitors of fungal sphingolipid synthesis as next-generation antifungal agents","volume":"62","author":"Haranahalli","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116283","article-title":"Impact of sphingolipid synthesis inhibition on the drug susceptibility patterns of Trichophyton species","volume":"109","author":"Arya","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib167","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/ph14121312","article-title":"Advances in antifungal drug development: an up-to-date mini review","volume":"14","author":"Bouz","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2025.06.013_bib168","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/AAC.00633-08","article-title":"Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A","volume":"53","author":"Aeed","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib169","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/jof9111115","article-title":"Structural and functional alterations caused by aureobasidin a in clinical resistant strains of Candida spp.","volume":"9","author":"Rollin-Pinheiro","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsomega.0c04980","article-title":"Cell rupture and morphogenesis control of the dimorphic yeast Candida albicans by nanostructured surfaces","volume":"6","author":"Kollu","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.apsb.2025.06.013_bib171","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.7164\/antibiotics.46.1414","article-title":"Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic","volume":"46","author":"Takesako","year":"1993","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.06.013_bib172","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/ph15070787","article-title":"Advances in antifungal development: discovery of new drugs and drug repurposing","volume":"15","author":"Kim","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2025.06.013_bib173","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41564-023-01561-1","article-title":"Brain glucose induces tolerance of Cryptococcus neoformans to amphotericin B during meningitis","volume":"9","author":"Chen","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib174","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/tde.12.134","article-title":"The oral delivery of amphotericin B","volume":"4","author":"Torrado","year":"2013","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2025.06.013_bib175","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.1117280109","article-title":"Amphotericin primarily kills yeast by simply binding ergosterol","volume":"109","author":"Gray","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 5","key":"10.1016\/j.apsb.2025.06.013_bib176","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler-Moore","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl B","key":"10.1016\/j.apsb.2025.06.013_bib177","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/28.suppl_B.63","article-title":"Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)","volume":"28","author":"Adler-Moore","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib178","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2710.1999.00220.x","article-title":"A comparative review of conventional and lipid formulations of amphotericin B","volume":"24","author":"Robinson","year":"1999","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.apsb.2025.06.013_bib179","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.intimp.2016.09.008","article-title":"Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii","volume":"40","author":"Batista-Duharte","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2025.06.013_bib180","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib181","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00724-19","article-title":"Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis","volume":"10","author":"Lu","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.06.013_bib182","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib183","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib184","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib185","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu070","article-title":"Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings","volume":"1","author":"Bahr","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib186","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114707","article-title":"Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51","volume":"243","author":"Xu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib188","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1021\/acs.jmedchem.4c00032","article-title":"Design, synthesis, bioactive evaluation, and molecular dynamics simulation of novel 4H-pyrano[3,2-c]pyridine analogues as potential sterol 14\u03b1-demethylase (CYP51) inhibitors","volume":"67","author":"Bao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105763","article-title":"Antifungal mechanisms of silver nanoparticles on mycotoxin producing rice false smut fungus","volume":"26","author":"Wen","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.apsb.2025.06.013_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011075","article-title":"H3K27me3 is vital for fungal development and secondary metabolite gene silencing, and substitutes for the loss of H3K9me3 in the plant pathogen Fusarium proliferatum","volume":"20","author":"Studt-Reinhold","year":"2024","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2025.06.013_bib191","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1021\/acsinfecdis.2c00096","article-title":"Jumonji histone demethylase inhibitor JIB-04 as a broad-spectrum antifungal agent","volume":"8","author":"Wang","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117028","article-title":"Discovery of new fungal jumonji H3K27 demethylase inhibitors for the treatment of Cryptococcus neoformans and Candida auris infections","volume":"281","author":"Liu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib193","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00022-23","article-title":"Newly discovered antimicrobial peptide Scyampcin(44\u201363) from Scylla paramamosain exhibits a multitargeted candidacidal mechanism in vitro and is effective in a murine model of vaginal candidiasis","volume":"67","author":"Zhou","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib194","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.apsb.2024.12.021","article-title":"Oral garlic-derived nanoparticles improve cancer immunotherapy","volume":"15","author":"Yang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1472-765X.1995.tb00397.x","article-title":"Antifungal effects of Allium sativum (garlic) extract against the Aspergillus species involved in otomycosis","volume":"20","author":"Pai","year":"1995","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib196","article-title":"Allicin shows antifungal efficacy against Cryptococcus neoformans by blocking the fungal cell membrane","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib197","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.fct.2004.06.007","article-title":"Effect of red pepper Capsicum annuum var. conoides and garlic Allium sativum on plasma lipid levels and cecal microflora in mice fed beef tallow","volume":"42","author":"Kuda","year":"2004","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.apsb.2025.06.013_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417519","article-title":"Combating black fungus: using allicin as a potent antifungal agent against mucorales","volume":"24","author":"Schier","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib199","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijantimicag.2008.09.014","article-title":"Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans","volume":"33","author":"An","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.apsb.2025.06.013_bib200","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/ps.4257","article-title":"Hog1p activation by marasmic acid through inhibition of the histidine kinase Sln1p","volume":"72","author":"Jacob","year":"2016","journal-title":"Pest Manag Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib201","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1574-6976.2011.00278.x","article-title":"Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance","volume":"36","author":"Silva","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib202","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jac\/dkm321","article-title":"The Candida glabrata putative sterol transporter gene CgAUS1 protects cells against azoles in the presence of serum","volume":"60","author":"Nakayama","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib203","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012076","article-title":"Candida auris undergoes adhesin-dependent and -independent cellular aggregation","volume":"20","author":"Pelletier","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2025.06.013_bib204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009794","article-title":"Aspergillus fumigatus biofilms: toward understanding how growth as a multicellular network increases antifungal resistance and disease progression","volume":"17","author":"Morelli","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2025.06.013_bib205","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1128\/AAC.00234-08","article-title":"Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells","volume":"52","author":"Seidler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib206","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MB-0017-2015","article-title":"Aspergillus biofilm in vitro and in vivo","volume":"3","author":"Beauvais","year":"2015","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.06.013_bib207","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1080\/14786419.2015.1118629","article-title":"A new flavone from Malaysia Borneo Marsdenia tinctoria","volume":"30","author":"Mohd Nasuha","year":"2016","journal-title":"Nat Prod Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib208","article-title":"Antifungal and antibiofilm activities of flavonoids against Candida albicans: focus on 3,2\u2032-dihydroxyflavone as a potential therapeutic agent","volume":"8","author":"Lee","year":"2024","journal-title":"Biofilms"},{"key":"10.1016\/j.apsb.2025.06.013_bib209","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acsinfecdis.0c00146","article-title":"Correction to inhibition of biofilm formation by Candida albicans and polymicrobial microorganisms by nepodin via hyphal-growth suppression","volume":"6","author":"Lee","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib210","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1567-1364.2009.00573.x","article-title":"Quorum sensing and fungal-bacterial interactions in Candida albicans: a communicative network regulating microbial coexistence and virulence","volume":"9","author":"De Sordi","year":"2009","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2023.04.010","article-title":"Characterization of an allosteric inhibitor of fungal-specific C-24 sterol methyltransferase to treat Candida albicans infections","volume":"30","author":"Jin","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib212","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00955-23","article-title":"Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model","volume":"68","author":"Jaromin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib213","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-drug-resistant to four classes of antifungal agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib214","doi-asserted-by":"crossref","first-page":"D894","DOI":"10.1093\/nar\/gkx1157","article-title":"aBiofilm: a resource of anti-biofilm agents and their potential implications in targeting antibiotic drug resistance","volume":"46","author":"Rajput","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib215","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1128\/EC.00144-12","article-title":"Farnesol and cyclic AMP signaling effects on the hypha-to-yeast transition in Candida albicans","volume":"11","author":"Lindsay","year":"2012","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.apsb.2025.06.013_bib216","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01531-24","article-title":"Ume6-dependent pathways of morphogenesis and biofilm formation in Candida auris","volume":"12","author":"Louvet","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.06.013_bib217","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/jof8080783","article-title":"Farnesol boosts the antifungal effect of fluconazole and modulates resistance in Candida auris through regulation of the CDR1 and ERG11 genes","volume":"8","author":"Dekkerov\u00e1","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib218","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1574-6976.2001.tb00582.x","article-title":"Conserved cAMP signaling cascades regulate fungal development and virulence","volume":"25","author":"D\u2019Souza","year":"2001","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib219","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/MMBR.64.4.746-785.2000","article-title":"Signal transduction cascades regulating fungal development and virulence","volume":"64","author":"Lengeler","year":"2000","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib220","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.013_bib221","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.bi.49.070180.001345","article-title":"Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis","volume":"49","author":"Jones","year":"1980","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2025.06.013_bib222","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/jof6030122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib223","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"J\u00f8rgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib224","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1186\/s12879-024-10295-2","article-title":"Correction: review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib225","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/TP.0000000000002353","article-title":"How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients","volume":"102","author":"Haidar","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.apsb.2025.06.013_bib226","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib227","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00999-18","article-title":"The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib228","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00434-21","article-title":"In vivo efficacy of olorofim against systemic Scedosporiosis and Lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib229","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","author":"Rivero-Menendez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib230","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkq177","article-title":"Uptake of T-2307, a novel arylamidine, in Candida albicans","volume":"65","author":"Nishikawa","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib231","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib232","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jac\/dkw095","article-title":"T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2","volume":"71","author":"Nishikawa","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib233","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00374-19","article-title":"The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes","volume":"63","author":"Yamashita","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib234","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/eri.09.67","article-title":"New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance","volume":"7","author":"Fera","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.apsb.2025.06.013_bib235","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib236","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1128\/AAC.04228-14","article-title":"The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib237","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00355-10","article-title":"T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena","volume":"54","author":"Yamada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib238","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib239","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ja.2016.106","article-title":"Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection","volume":"70","author":"Nakamura","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.06.013_bib240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ja.2016.107","article-title":"ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833","volume":"70","author":"Nakamura","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.06.013_bib241","doi-asserted-by":"crossref","first-page":"e00807","DOI":"10.1128\/AAC.00807-19","article-title":"The siderophore transporter Sit1 determines ssusceptibility to the antifungal VL-2397","volume":"63","author":"Dietl","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib242","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00239-004-0218-1","article-title":"Comparison of the yeast proteome to other fungal genomes to find core fungal genes","volume":"60","author":"Hsiang","year":"2005","journal-title":"J Mol Evol"},{"key":"10.1016\/j.apsb.2025.06.013_bib243","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00969-19","article-title":"First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults","volume":"63","author":"Mammen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib244","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/jof8090909","article-title":"GR-2397: review of the novel siderophore-like antifungal agent for the treatment of invasive aspergillosis","volume":"8","author":"Shaw","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413659","article-title":"Alkaloids from Waltheria spp. (Malvaceae): chemosystematic aspects, biosynthesis, total synthesis, and biological activities","volume":"25","author":"Silva","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib246","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ptr.2078","article-title":"Bioassay-guided isolation of antifungal alkaloids from Melochia odorata","volume":"21","author":"Emile","year":"2007","journal-title":"Phytother Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib247","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acs.jnatprod.5b00896","article-title":"Antifungal quinoline alkaloids from Waltheria indica","volume":"79","author":"Cretton","year":"2016","journal-title":"J Nat Prod"},{"key":"10.1016\/j.apsb.2025.06.013_bib248","doi-asserted-by":"crossref","first-page":"12146","DOI":"10.1074\/jbc.RA119.007766","article-title":"High-throughput screening for phosphatidylserine decarboxylase inhibitors using a distyrylbenzene-bis-aldehyde (DSB-3)-based fluorescence assay","volume":"294","author":"Hendricson","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib249","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.bbamem.2018.05.016","article-title":"Phosphatidylserine decarboxylase governs plasma membrane fluidity and impacts drug susceptibilities of Candida albicans cells","volume":"1860","author":"Khandelwal","year":"2018","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.apsb.2025.06.013_bib250","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41418-024-01374-7","article-title":"PHGDH\/SYK: a hub integrating anti-fungal immunity and serine metabolism","volume":"31","author":"Zhang","year":"2024","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2025.06.013_bib251","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fmicb.2020.01383","article-title":"The essential thioredoxin reductase of the human pathogenic mold Aspergillus fumigatus is a promising antifungal target","volume":"11","author":"Binder","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib252","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/mmy\/myaa094","article-title":"The fungal-specific subunit i\/j of F1Fo-ATP synthase stimulates the pathogenicity of Candida albicans independent of oxidative phosphorylation","volume":"59","author":"Zhao","year":"2021","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib253","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1038\/s41467-021-26313-9","article-title":"The \u03b4 subunit of F1Fo-ATP synthase is required for pathogenicity of Candida albicans","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.06.013_bib254","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmicb.2020.00213","article-title":"SPT20 regulates the Hog1\u2013MAPK pathway and is involved in Candida albicans response to hyperosmotic stress","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib255","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3389\/fmicb.2019.03018","article-title":"Evolutionary histories of type III polyketide synthases in fungi","volume":"10","author":"Navarro-Mu\u00f1oz","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib256","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03551-22","article-title":"Dysregulating PHO signaling via the CDK machinery differentially impacts energy metabolism, calcineurin signaling, and virulence in Cryptococcus neoformans","volume":"14","author":"Bowring","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.06.013_bib257","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41564-024-01662-5","article-title":"A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens","volume":"9","author":"Zhou","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114819","article-title":"Target- and prodrug-based design for fungal diseases and cancer-associated fungal infections","volume":"197","author":"Liu","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib259","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113524","article-title":"Lanosterol 14\u03b1-demethylase (CYP51)\/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections","volume":"221","author":"Zhu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113961","article-title":"Heat shock protein 90 (HSP90)\/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans","volume":"227","author":"Li","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib261","doi-asserted-by":"crossref","first-page":"26302","DOI":"10.1039\/C9RA03713F","article-title":"Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors","volume":"9","author":"Dong","year":"2019","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2025.06.013_bib262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065928","article-title":"Discovery of a novel dual fungal CYP51\/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy","volume":"8","author":"Hoobler","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.06.013_bib263","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11427-023-2322-3","article-title":"Progress in immunotherapy","volume":"66","author":"Sun","year":"2023","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib264","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau5480","article-title":"Antimicrobial peptides: application informed by evolution","volume":"368","author":"Lazzaro","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.06.013_bib265","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.apsb.2023.12.016","article-title":"Harnessing antimicrobial peptide-coupled photosensitizer to combat drug-resistant biofilm infections through enhanced photodynamic therapy","volume":"14","author":"Fan","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.06.013_bib266","first-page":"48","article-title":"Antimicrobial peptides: mechanism of action, activity and clinical potential","volume":"8","author":"Zhang","year":"2021","journal-title":"Mil Med Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib267","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1405760","article-title":"Recent advances in the therapeutic potential of cathelicidins","volume":"15","author":"Guerra","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib268","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3389\/fimmu.2020.02177","article-title":"Innate inspiration: antifungal peptides and other immunotherapeutics from the host immune response","volume":"11","author":"Mercer","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib269","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","article-title":"Antimicrobial host defence peptides: functions and clinical potential","volume":"19","author":"Mookherjee","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.06.013_bib270","article-title":"Correction to: NP213 (Novexatin\u00ae): a unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile","volume":"61","year":"2023","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib271","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1741-7015-7-44","article-title":"Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)","volume":"7","author":"Velden","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib272","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1034\/j.1600-051X.2002.291201.x","article-title":"Safety and clinical effects of topical histatin gels in humans with experimental gingivitis","volume":"29","author":"Paquette","year":"2002","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.apsb.2025.06.013_bib273","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1034\/j.1600-051x.2002.290212.x","article-title":"Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study","volume":"29","author":"Van Dyke","year":"2002","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.apsb.2025.06.013_bib274","article-title":"The effects of antimicrobial peptide Nal-P-113 on inhibiting periodontal pathogens and improving periodontal status","volume":"2018","author":"Wang","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2025.06.013_bib275","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/593185","article-title":"Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream","volume":"47","author":"Lipsky","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib276","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/bcp.14181","article-title":"Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions","volume":"86","author":"Rijsbergen","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2025.06.013_bib277","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1164\/rccm.200504-656OC","article-title":"A randomized double-blind trial of iseganan in prevention of ventilator-associated pneumonia","volume":"173","author":"Kollef","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib278","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/AAC.03513-14","article-title":"LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus","volume":"59","author":"Nilsson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib279","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of interferon-gamma","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib280","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2334-14-166","article-title":"Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series","volume":"14","author":"Delsing","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib281","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib282","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00006454-199609000-00021","article-title":"Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma-interferon and itraconazole","volume":"15","author":"Pasic","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.apsb.2025.06.013_bib283","doi-asserted-by":"crossref","first-page":"E137","DOI":"10.1086\/320158","article-title":"Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease","volume":"32","author":"Saulsbury","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib284","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1089\/088922201750251981","article-title":"A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease","volume":"17","author":"Riddell","year":"2001","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.apsb.2025.06.013_bib285","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jac\/dkf206","article-title":"Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient","volume":"50","author":"Bodasing","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib286","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.apsb.2025.06.013_bib287","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/517077","article-title":"Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia","volume":"26","author":"Poynton","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib288","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cncr.21142","article-title":"Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia","volume":"104","author":"Dignani","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2025.06.013_bib289","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/j.1600-6143.2010.03094.x","article-title":"Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients","volume":"10","author":"Armstrong-James","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.apsb.2025.06.013_bib290","first-page":"783","article-title":"Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies","volume":"14","author":"Grigull","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.apsb.2025.06.013_bib291","doi-asserted-by":"crossref","DOI":"10.1016\/j.cimid.2020.101417","article-title":"Complete clinical remission of invasive Candida infection with CARD9 deficiency after G-CSF treatment","volume":"70","author":"Du","year":"2020","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib292","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF01691218","article-title":"Role of granulocyte colony-stimulating factor in the treatment of mucormycosis","volume":"15","author":"Sahin","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib293","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1182\/blood.V78.5.1190.1190","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse","volume":"78","author":"B\u00fcchner","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.06.013_bib294","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2014.60.5121","article-title":"Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial","volume":"33","author":"Wan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2025.06.013_bib295","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF01973597","article-title":"Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection","volume":"13","author":"Bodey","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib296","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib297","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1310\/LF5T-WYY7-0U3E-G8BQ","article-title":"Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study","volume":"1","author":"Vazquez","year":"2000","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.apsb.2025.06.013_bib298","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V78.4.907.907","article-title":"Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections","volume":"78","author":"Nemunaitis","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.06.013_bib299","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/cid\/ciy185","article-title":"A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis\u2014a phase 2 randomized, double-blind, placebo-controlled trial","volume":"66","author":"Edwards","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/mmy\/myx139","article-title":"Candida vaginitis: virulence, host response and vaccine prospects","volume":"56","author":"De Bernardis","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib301","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(89)90197-7","article-title":"Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis","volume":"7","author":"Levy","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2025.06.013_bib302","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1164\/ajrccm\/148.3.656","article-title":"Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group","volume":"148","author":"Pappagianis","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib303","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1128\/AAC.38.7.1507","article-title":"Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans","volume":"38","author":"Zebedee","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib304","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/503428","article-title":"A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis","volume":"42","author":"Pachl","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib305","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.013_bib306","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"Seif","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib307","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/microorganisms9091886","article-title":"Titan cells and yeast forms of Cryptococcus neoformans and Cryptococcus gattii Are recognized by GXMR-CAR","volume":"9","author":"Dos Santos","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2025.06.013_bib308","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/08880018.2013.868562","article-title":"Granulocyte transfusions for children with infection and neutropenia or granulocyte dysfunction","volume":"31","author":"D\u00edaz","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.apsb.2025.06.013_bib309","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2015.53","article-title":"Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience","volume":"50","author":"Nikolajeva","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.apsb.2025.06.013_bib310","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib311","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1083215","article-title":"Familial CD45RA\u2013 T cells to treat severe refractory infections in immunocompromised patients","volume":"10","author":"Al-Akioui Sanz","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib312","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.06.013_bib313","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s10875-019-00687-4","article-title":"Novel gain-of-function mutation in Stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib","volume":"39","author":"Al Shehri","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib314","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/mmy\/myaa015","article-title":"NP213 (Novexatin\u00ae): a unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile","volume":"58","author":"Mercer","year":"2020","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib315","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02117-18","article-title":"Improved methods for assessing therapeutic potential of antifungal agents against dermatophytes and their application in the development of NP213, a novel onychomycosis therapy candidate","volume":"63","author":"Mercer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib316","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10534-010-9322-4","article-title":"The human lactoferrin-derived peptide hLF1-11 primes monocytes for an enhanced TLR-mediated immune response","volume":"23","author":"van der Does","year":"2010","journal-title":"Biometals"},{"key":"10.1016\/j.apsb.2025.06.013_bib317","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167470","article-title":"Inhibition of Candida albicans biofilm fformation by the synthetic lactoferricin derived peptide hLF1-11","volume":"11","author":"Morici","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.06.013_bib318","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1128\/AAC.47.1.262-267.2003","article-title":"Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species","volume":"47","author":"Lupetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib319","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1086\/522427","article-title":"Human lactoferrin-derived peptide\u2019s antifungal activities against disseminated Candida albicans infection","volume":"196","author":"Lupetti","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib320","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.45.5.1367-1373.2001","article-title":"Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5","volume":"45","author":"Rothstein","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib321","article-title":"The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization","volume":"8","author":"Ji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.06.013_bib322","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-3011.2005.00265.x","article-title":"Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2","volume":"66","author":"Catania","year":"2005","journal-title":"J Pept Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib323","doi-asserted-by":"crossref","first-page":"17856","DOI":"10.1021\/acsomega.3c00850","article-title":"Interaction of pexiganan (MSI-78)-derived analogues reduces inflammation and TLR4-mediated cytokine secretion: a comparative study","volume":"8","author":"Cohen","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.apsb.2025.06.013_bib324","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/bi400087n","article-title":"Lipid composition-dependent membrane fragmentation and pore-forming mechanisms of membrane disruption by pexiganan (MSI-78)","volume":"52","author":"Lee","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2025.06.013_bib325","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.bbamem.2008.10.009","article-title":"Structure, membrane orientation, mechanism, and function of pexiganan\u2014a highly potent antimicrobial peptide designed from magainin","volume":"1788","author":"Gottler","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2025.06.013_bib326","article-title":"Antifungal immunity: advances in PRR recognition, adaptive responses, and immune-based therapies","author":"Zhou","year":"2025","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib327","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl2016","article-title":"Interferon-\u03b3 and infectious diseases: lessons and prospects","volume":"384","author":"Casanova","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.06.013_bib328","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases","volume":"9","author":"Kak","year":"2018","journal-title":"Biomol Concepts"},{"key":"10.1016\/j.apsb.2025.06.013_bib329","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/425121","article-title":"Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy","volume":"39","author":"Netea","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib330","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1099\/0022-1317-51-1-70","article-title":"Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery","volume":"51","author":"Ellis","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib331","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1183\/09031936.06.00021705","article-title":"Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis","volume":"27","author":"Kelleher","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2025.06.013_bib332","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00221-009-1831-4","article-title":"Catch the moment: multisensory enhancement of rapid visual events by sound","volume":"198","author":"Chen","year":"2009","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib333","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib334","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.4049\/jimmunol.173.11.6858","article-title":"Gene expression profiling of host response in models of acute HIV infection","volume":"173","author":"Bosinger","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib335","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/infdis\/163.3.579","article-title":"Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils","volume":"163","author":"Roilides","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib336","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1128\/AAC.42.10.2467","article-title":"Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression","volume":"42","author":"Graybill","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib337","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/10245332.1999.11746453","volume":"4","author":"Hazel","year":"1999","journal-title":"Hematology"},{"key":"10.1016\/j.apsb.2025.06.013_bib338","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib339","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.4049\/jimmunol.1501512","article-title":"Local GM-CSF-dependent differentiation and activation of pulmonary dendritic cells and macrophages protect against progressive cryptococcal lung infection in mice","volume":"196","author":"Chen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib340","article-title":"GM-CSF-mediated epithelial\u2013immune cell crosstalk orchestrates pulmonary immunity to Aspergillus fumigatus","author":"Mills","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.apsb.2025.06.013_bib341","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/169.2.369","article-title":"Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat","volume":"169","author":"Vitt","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib342","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1128\/AAC.38.9.2162","article-title":"Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans","volume":"38","author":"Nassar","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib343","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11427-022-2230-4","article-title":"Current progress in the development of prophylactic and therapeutic vaccines","volume":"66","author":"Li","year":"2023","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib344","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1016\/j.vaccine.2012.10.038","article-title":"NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults","volume":"30","author":"Schmidt","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2025.06.013_bib345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0050064","article-title":"Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells","volume":"5","author":"Phan","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib346","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1086\/504691","article-title":"Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis","volume":"194","author":"Spellberg","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib347","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2012.04.069","article-title":"A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models","volume":"30","author":"De Bernardis","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2025.06.013_bib348","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgac248","article-title":"Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis","volume":"1","author":"Rayens","year":"2022","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.apsb.2025.06.013_bib349","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.925821","article-title":"Antibodies targeting Candida albicans Als3 and Hyr1 antigens protect neonatal mice from candidiasis","volume":"13","author":"Singh","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib350","doi-asserted-by":"crossref","DOI":"10.3389\/ffunb.2023.1241539","article-title":"Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance","volume":"4","author":"Kumar","year":"2023","journal-title":"Front Fungal Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib351","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114775","article-title":"Fungal infections: immune defense, immunotherapies and vaccines","volume":"196","author":"Loh","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.06.013_bib352","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s11427-024-2639-3","article-title":"mRNA vaccine technology for infectious diseases and beyond","volume":"67","author":"Hao","year":"2024","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib353","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/diagnostics11050758","article-title":"A novel, inexpensive in-house immunochromatographic strip test for cryptococcosis based on the cryptococcal glucuronoxylomannan specific monoclonal antibody 18B7","volume":"11","author":"Sathongdejwisit","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.apsb.2025.06.013_bib354","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib355","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/403121","article-title":"Human monoclonal antibody-based therapy in the treatment of invasive candidiasis","volume":"2013","author":"Bugli","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.apsb.2025.06.013_bib356","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98659-5","article-title":"A new humanized antibody is effective against pathogenic fungi in vitro","volume":"11","author":"Di Mambro","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.06.013_bib357","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1039\/D2RA07217C","article-title":"AFM evaluation of a humanized recombinant antibody affecting C. auris cell wall and stability","volume":"13","author":"Vanzolini","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.apsb.2025.06.013_bib358","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/509891","article-title":"Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis","volume":"195","author":"De Bernardis","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib359","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.0711918105","article-title":"The PD-1\/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum","volume":"105","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.013_bib360","doi-asserted-by":"crossref","DOI":"10.1186\/cc12711","article-title":"Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis","volume":"17","author":"Chang","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.apsb.2025.06.013_bib361","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/IAI.68.8.4624-4630.2000","article-title":"CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response","volume":"68","author":"McGaha","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.apsb.2025.06.013_bib362","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib363","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nm.4260","article-title":"JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression","volume":"23","author":"Zhao","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.06.013_bib364","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/pharmaceutics15071780","article-title":"Disrupting the Dok3\u2013Card9 interaction with synthetic peptides enhances antifungal effector functions of human neutrophils","volume":"15","author":"Loh","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.06.013_bib365","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.immuni.2023.06.002","article-title":"The nucleotide receptor STING translocates to the phagosomes to negatively regulate anti-fungal immunity","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2025.06.013_bib366","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1007\/s00253-021-11407-7","article-title":"Drug repurposing strategies in the development of potential antifungal agents","volume":"105","author":"Zhang","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.apsb.2025.06.013_bib367","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/mmy\/myv059","article-title":"In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction","volume":"53","author":"Rossato","year":"2015","journal-title":"Med Mycol"},{"key":"10.1016\/j.apsb.2025.06.013_bib368","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001759","article-title":"Analysis of possible pathways on the mechanism of action of minocycline and doxycycline against strains of Candida spp. resistant to fluconazole","volume":"72","author":"da Silva","year":"2023","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib369","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/infdis\/136.2.263","article-title":"Antifungal activity of four tetracycline analogues against Candida albicans in vitro: potentiation by amphotericin B","volume":"136","author":"Lew","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib370","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1567-1364.2010.00664.x","article-title":"The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: an in vitro interaction of antifungal and antibacterial agents","volume":"10","author":"Shi","year":"2010","journal-title":"FEMS Yeast Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib371","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1128\/AAC.02680-13","article-title":"New insights into the in vitro susceptibility of Pythium insidiosum","volume":"58","author":"Loreto","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib372","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00290-20","article-title":"In vitro and in vivo study on the synergistic effect of minocycline and azoles against pathogenic fungi","volume":"64","author":"Gao","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib373","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1164\/ajrccm\/147.1.153","article-title":"A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis","volume":"147","author":"Kadota","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib374","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.56.721","article-title":"Effect of 14-membered macrolide compounds on monocyte to macrophage differentiation","volume":"56","author":"Sunazuka","year":"2003","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.06.013_bib375","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/infdis\/jiv157","article-title":"Macrolides promote CCL2-mediated macrophage recruitment and clearance of nasopharyngeal pneumococcal colonization in mice","volume":"212","author":"Iwanaga","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib376","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02364-18","article-title":"Macrolides inhibit capsule formation of highly virulent Cryptococcus gattii and promote innate immune susceptibility","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib377","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10096-014-2296-3","article-title":"Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?.","volume":"34","author":"Dalhoff","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib378","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1086\/315649","article-title":"Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans","volume":"182","author":"Harrison","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.apsb.2025.06.013_bib379","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09273940600976953","article-title":"In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections","volume":"14","author":"Ozdek","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.apsb.2025.06.013_bib380","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/dkn473","article-title":"Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus","volume":"63","author":"Stergiopoulou","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib381","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1128\/AAC.00735-07","article-title":"Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus","volume":"52","author":"Stergiopoulou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib382","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/W09-112","article-title":"Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits","volume":"56","author":"Deren","year":"2010","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib383","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/myc.12025","article-title":"Ciprofloxacin shows synergism with classical antifungals against Histoplasma capsulatum var. capsulatum and Coccidioides posadasii","volume":"56","author":"Brilhante","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.apsb.2025.06.013_bib384","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1128\/AAC.00548-11","article-title":"Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus","volume":"55","author":"Stergiopoulou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib385","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1128\/AAC.36.12.2778","article-title":"DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs","volume":"36","author":"Shen","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib386","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1016\/S0021-9258(18)42185-0","article-title":"Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast","volume":"267","author":"Elsea","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib387","doi-asserted-by":"crossref","first-page":"20359","DOI":"10.1074\/jbc.270.35.20359","article-title":"A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors","volume":"270","author":"Hsiung","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib388","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1074\/jbc.275.11.7980","article-title":"A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons","volume":"275","author":"Dong","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib389","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1074\/jbc.274.11.7292","article-title":"Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme\u2013DNA and drug interactions","volume":"274","author":"Strumberg","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.06.013_bib390","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/cb100399x","article-title":"Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules","volume":"6","author":"Baxter","year":"2011","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2025.06.013_bib391","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1128\/AAC.01061-16","article-title":"The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of Cryptococcosis","volume":"60","author":"Koselny","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib392","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.06.013_bib393","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1073\/pnas.1521548113","article-title":"Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers","volume":"113","author":"Mullarky","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.06.013_bib394","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00727-22","article-title":"Repurposing of MitoTam: novel anti-cancer drug candidate exhibits potent activity against major protozoan and fungal pathogens","volume":"66","author":"Arbon","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib395","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231197957","article-title":"Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I\/Ib clinical trial","volume":"15","author":"Bielcikova","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.apsb.2025.06.013_bib396","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.3390\/ijms21217941","article-title":"Mitocans revisited: mitochondrial targeting as efficient anti-cancer therapy","volume":"21","author":"Dong","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib397","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.3390\/cancers15184476","article-title":"MitoTam-01 trial: mitochondrial targeting as plausible approach to cancer therapy. Comment on Yap et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 2023, 29, 115-126","volume":"15","author":"Neuzil","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2025.06.013_bib398","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.progpolymsci.2017.03.001","article-title":"Quaternary ammonium-based biomedical materials: state-of-the-art, toxicological aspects and antimicrobial resistance","volume":"71","author":"Jiao","year":"2017","journal-title":"Prog Polym Sci"},{"key":"10.1016\/j.apsb.2025.06.013_bib399","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042355","article-title":"An ORMOSIL-containing orthodontic acrylic resin with concomitant improvements in antimicrobial and fracture toughness properties","volume":"7","author":"Gong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.06.013_bib400","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.actbio.2012.05.031","article-title":"Quaternary ammonium silane-functionalized, methacrylate resin composition with antimicrobial activities and self-repair potential","volume":"8","author":"Gong","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2025.06.013_bib401","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.joen.2014.03.010","article-title":"In vitro evaluation of antibacterial effect of AH Plus incorporated with quaternary ammonium epoxy silicate against Enterococcus faecalis","volume":"40","author":"Gong","year":"2014","journal-title":"J Endod"},{"key":"10.1016\/j.apsb.2025.06.013_bib402","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joen.2013.12.021","article-title":"Antibiofilm effects of endodontic sealers containing quaternary ammonium polyethylenimine nanoparticles","volume":"40","author":"Barros","year":"2014","journal-title":"J Endod"},{"key":"10.1016\/j.apsb.2025.06.013_bib403","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/iej.12054","article-title":"Towards antibacterial endodontic sealers using quaternary ammonium nanoparticles","volume":"46","author":"Kesler Shvero","year":"2013","journal-title":"Int Endod J"},{"key":"10.1016\/j.apsb.2025.06.013_bib404","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.antiviral.2016.05.004","article-title":"Anti-herpesviral effects of a novel broad range anti-microbial quaternary ammonium silane, K21","volume":"131","author":"Gulve","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2017.09.011","article-title":"Use of whole genome deep sequencing to define emerging minority variants in virus envelope genes in herpesvirus treated with novel antimicrobial K21","volume":"146","author":"Tweedy","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2025.06.013_bib406","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3389\/fmicb.2019.01021","article-title":"K21 compound, a potent antifungal agent: implications for the treatment of fluconazole-resistant HIV-associated Candida species","volume":"10","author":"John","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.06.013_bib407","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00263-19","article-title":"Repurposing of ribavirin as an adjunct therapy against invasive Candida Strains in an in vitro study","volume":"63","author":"Yousfi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.06.013_bib408","article-title":"Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525004332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:05:15Z","timestamp":1755623115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525004332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":408,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2211383525004332"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.013","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}